← Leaderboards
James M. Gallo
Fox Chase Cancer Center
$7,670,541
Attributed
$8,395,572
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,395,572 · 7
By mechanism
R01$7,139,525 · 5
U01$1,087,547 · 1
R21$168,500 · 1
Top collaborators
- Marc R. Birtwistle2 shared
- Yeh-Hsing Lao2 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsGliomaBaseIn VivoInvestigationDesignTumorHybridsCharacteristicsBrain NeoplasmsPropertyBehaviorMeasurementDrug KineticsMolecularCytotoxicSeriesPharmacodynamicsAntineoplastic AgentsEpidermal Growth Factor ReceptorEnsurePre-ClinicalCellsEfflux Pump
Grant awards (29)
Cell State Network-Directed Therapy$529,214
U01 · FY2025 · CA
Cell State Network-Directed Therapy$558,333
U01 · FY2024 · CA
Interactions Between Cytotoxic and Antiangiogenic Drugs$229,022
R01 · FY2015 · CA · contact PI
Interactions Between Cytotoxic and Antiangiogenic Drugs$222,152
R01 · FY2014 · CA · contact PI
Function of the MRP Family$433,724
R01 · FY2013 · CA · contact PI
Interactions Between Cytotoxic and Antiangiogenic Drugs$215,281
R01 · FY2013 · CA · contact PI
Function of the MRP Family$463,871
R01 · FY2012 · CA · contact PI
Development of Targeted Anticancer Drugs$341,162
R01 · FY2012 · CA · contact PI
Interactions Between Cytotoxic and Antiangiogenic Drugs$229,022
R01 · FY2012 · CA · contact PI
Function of the MRP Family$430,485
R01 · FY2011 · CA · contact PI
Functions of MRP2 and MRP3 in Drug Disposition$343,127
R01 · FY2011 · CA · contact PI
Development of Targeted Anticancer Drugs$341,162
R01 · FY2011 · CA · contact PI
Interactions Between Cytotoxic and Antiangiogenic Drugs$229,022
R01 · FY2011 · CA · contact PI
Development of Targeted Anticancer Drugs$351,713
R01 · FY2010 · CA · contact PI
Development of Targeted Anticancer Drugs$313,806
R01 · FY2009 · CA · contact PI
Development of Targeted Anticancer Drugs$294,930
R01 · FY2009 · CA · contact PI
Development of Targeted Anticancer Drugs$33,546
R01 · FY2009 · CA · contact PI
Development of Targeted Anticancer Drugs$311,250
R01 · FY2008 · CA · contact PI
Interactions Between Cytotoxic and Antiangiogenic Drugs$203,350
R01 · FY2008 · CA · contact PI
Interactions Between Cytotoxic and Antiangiogenic Drugs$203,350
R01 · FY2007 · CA · contact PI
Cells Designed to Deliver Anticancer Drugs by Apoptosis$260,726
R01 · FY2006 · CA · contact PI
Interactions Between Cytotoxic and Antiangiogenic Drugs$209,423
R01 · FY2006 · CA · contact PI
Cells Designed to Deliver Anticancer Drugs by Apoptosis$267,000
R01 · FY2005 · CA
Interactions Between Cytotoxic and Antiangiogenic Drugs$214,463
R01 · FY2005 · CA
Cells Designed to Deliver Anticancer Drugs by Apoptosis$302,600
R01 · FY2004 · CA
Interactions Between Cytotoxic and Antiangiogenic Drugs$214,463
R01 · FY2004 · CA
Cells Designed to Deliver Anticancer Drugs by Apoptosis$302,600
R01 · FY2003 · CA
INTERACTIONS BETWEEN CYTOTOXIC AND ANTIANGIOGENIC DRUGS$178,275
R01 · FY2000 · CA
OPTIMIZED CANCER CHEMOTHERAPY VIA PHARMACODYNAMIC MODELS$168,500
R21 · FY2000 · CA